JPET # 110510

Introduction
In rodents, adult neurogenesis occurs in discrete regions of the brain, particularly in the subventricular zone, giving rise to granule cells in the olfactory bulb, and in the subgranular zone, generating new granule cells in the dentate gyrus of the hippocampus (Altman and Das, 1965; Kaplan and Hinds, 1977; Kuhn et al., 1996) . Hippocampal neuronal cells in the adult are formed through replication and differentiation from pluripotent neural progenitor cells . Immature neurons migrate to the granule cell layer and mature over a period of weeks into granule cells that form functional connections (van Praag et al., 2002) .
Hippocampal neurogenesis has emerged as a central therapeutic target for antidepressant agents, based on accumulating evidence supporting the neurogenic theory of depression (Jacobs et al., 2000; Kempermann, 2002) . All known classes of clinical antidepressant drugs, including tricyclics, monoamine oxidase inhibitors and selective serotonin reuptake inhibitors (SSRIs), have been shown to increase cell proliferation in the hippocampus (Malberg et al., 2000; Santarelli et al., 2003) . Moreover, Santarelli et al. (2003) provided evidence, by irradiation of the hippocampus, that hippocampal neurogenesis is required to achieve the behavioral effects of antidepressants in animal models. Hippocampal cell proliferation is decreased under conditions of chronic stress, and this effect is reversed by antidepressant treatment (reviewed by Dranovsky and Hen, 2006; Warner-Schmidt and Duman, 2006) . Imaging studies have also shown that depressed human subjects exhibit volume loss and atrophy of the hippocampus (Sheline, 2003) . In addition to a role in mood disorders, increased neurogenesis may be a repair mechanism in stroke (Lichtenwalner and Parent, 2006) and traumatic brain injury (Emery et al., 2005) and also contribute to learning and memory (Shors et al., 2001) .
A number of factors and intersecting pathways influence the drug-induced stimulation of neurogenesis in the hippocampus. For example, antidepressant drugs activate intracellular second messenger systems, leading to the activation of transcription factors and neurotrophic This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on as DOI: 10.1124 at ASPET Journals on July 9, 2017 jpet.aspetjournals.org Downloaded from JPET # 110510 5 factors, finally culminating in increased numbers of new neurons in the hippocampus (WarnerSchmidt and Duman, 2006) . The complexity of neurogenic regulation opens the possibility that multiple therapeutic targets may exist, on the one hand, but also makes predicting the effect of any agent acting on a particular target difficult and complicates the interpretation of in vitro screening approaches based on receptor binding or modulation of enzyme activities. It is therefore important to validate in vivo the neurogenic activity of agents identified through in vitro screens; moreover, in vivo screening might uncover novel mechanisms that contribute to neurogenesis arising from unanticipated connectivity relationships in the whole organism.
Measurement of neurogenesis in vivo has been problematic, however. Early studies used [
3 H]-thymidine to label dividing cells (Altman and Das, 1965; Kaplan and Hinds, 1977) , while the most commonly used method currently for measuring cell proliferation in the hippocampus involves injecting animals with bromodeoxyuridine (BrdU) 24 hours before sacrifice (Kuhn et al., 1996; Cameron and McKay, 2001) . The hippocampus is then serially sectioned for immunohistochemical detection of BrdU, as well as double-immunohistochemical labeling with neuronal markers to establish the phenotype of BrdU-positive cells. BrdU-labeling has limitations, however, such as a short half-life and rapid clearance of BrdU from the brain, variable efficiency of BrdU entry into cellular precursor pools, and the requirement for high doses to accurately estimate the number of proliferating cells (Cameron and McKay, 2001; Gould and Gross, 2002) . Moreover, immunohistochemical enumeration of BrdU-labeled cells in the entire hippocampus is labor intensive, so that throughput with BrdU-labeling is not sufficient for use in broad screening or testing of potential neurogenic agents.
Here, we describe the application of heavy water ( 2 H 2 O) as a DNA label for quantifying the proliferation of hippocampal progenitor cells as well as their survival and maturation into neurons. We have previously shown in humans and experimental animals that deuterium ( 2 H) from 2 H 2 O is incorporated constitutively into the deoxyribose moiety of purine deoxyribonucleotides in genomic DNA through the de novo nucleotide synthesis pathway (Fig 1) This article has not been copyedited and formatted. The final version may differ from this version. Jones and Leatherdale, 1991) , intake of up to 20% 2 H 2 O has no apparent phenotypic or behavioral effects. For protocols involving label incorporation in hippocampal progenitor cells, mice were labeled continuously for up to 1 year. In a separate study, total hippocampal tissue was isolated after 3, 7, or 14 days of labeling. Animals that received drug treatment were labeled during the final 7-10 days of treatment. For studies that assessed proliferation of mature neurons, animals were labeled with 10% 2 H 2 O for 3 weeks, after which time the label was discontinued and animals were sacrificed 4 weeks later.
Drug Treatments
This article has not been copyedited and formatted. The final version may differ from this version. respectively. These concentrations were calculated to achieve a dose of 10 mg/kg/day for fluoxetine and venlafaxine and 20 mg/kg/day for imipramine, based on the average cage consumption of water (3 ml / 30g mouse or 25 ml / 250g rat). Treatment with anti-depressant drugs was continued for 3-5 weeks.
Various approved drugs were screened for neurogenic activity (Table 1 ). These agents were selected based on long-standing use in humans and on the recognition of having several therapeutic actions (i.e., pleiotropic effects). This effort was intended to be a proof-of-concept study to demonstrate 'indications discovery', i.e. ability to find unexpected actions of agents with potential use in a new indication. The doses selected were based on use in published preclinical studies with these agents, and the concentrations in food or water were calculated based on the average cage consumption of food (3 g / 30g mouse) and water (3 ml / 30g mouse). As a followup study after initial screening, a potential 'class' effect for one of the agents (topiramate) tested in the initial screen was investigated by treating mice orally for 3 weeks with one of 11 other 
Isolation of nuclei from mature neurons and sorting NeuN positive nuclei by flow cytometry
Neuronal nuclei were isolated from frozen hippocampal tissue by a modification of a recentlydescribed method (Spalding et al., 2005) . Briefly, tissue was homogenized in 1 ml lysis buffer conjugate in 100 µl blocking buffer (PBS / 0.5% BSA / 10% normal goat serum) with 300 µl NeuN antibody (1 mg/ml; diluted 1:250 in PBS) and incubating at room temperature for 5 minutes. The suspension of nuclei (1 ml) was added and incubated at 4°C for 1 hour. The nuclei were then washed twice with 3 ml PBS by centrifuging at 1000 x g for 10 min. Propidium iodide was used to stain DNA, and neuronal nuclei were sorted as a homogeneous population of NeuN bright cells, using a Coulter Epics Elite sorter (Beckman Coulter) with gates set for PIpositive single nuclei.
Measurement of cell proliferation
Gas chromatographic/mass spectrometric (GC/MS) analyses were performed as described previously (Neese et al., 2002; Busch et al., 2004) and hydrolyzed enzymatically to free deoxyribonucleosides. The deoxyribose moiety of purine deoxyribonucleosides was converted to the pentafluorobenzyl tetraacetate derivative and analyzed by GC/MS in the negative chemical ionization mode, using an Agilent (Palo Alto, CA) model 5973 mass spectrometer and a 6890 gas chromatograph fitted with a db-225 column.
Selected ion monitoring was performed with mass-to-charge ratios (m/z) of 435 for the M0 and 436 for M1 mass isotopomer, respectively. Incorporation of 2 H from 2 H 2 O into purine deoxyribose was quantified as the molar excess fraction M1 (EM1), i.e. the increase over natural abundance (background) defined as the fractional M1 value for an unlabeled DNA standard from calf thymus.
The fraction of newly labeled cells was calculated as the ratio of excess 2 H enrichment (EM1) in isolated cells to the corresponding enrichment in bone marrow DNA (an essentially fully turnedover tissue after 7-10 days of labeling, thereby representing an asymptotic enrichment value for comparison to other tissues), as described previously (Neese et al., 2002) . For studies involving shorter labeling periods than 7-10 days, 2 H incorporation in fully turned-over tissue DNA was estimated from body water 2 H enrichments at sacrifice, based on previously established relationships between body water 2 H enrichments and asymptotic labeling in tissues (Neese et al., 2002) .
Statistical Analysis
For label incorporation curves, the data were fit by nonlinear regression analysis (SigmaPlot). 
Results
Flow cytometric analysis of gradient-enriched hippocampal progenitor cells
Measurement of 2 H incorporation into the DNA of hippocampal progenitor cells requires isolation of this cell population from intact tissue. To this end, progenitor cells were isolated from the hippocampus of Swiss Webster mice by Percoll gradient fractionation (Fig. 2A) ; the isolated cells were fixed and permeabilized, stained for specific intracellular markers of progenitor cells, nestin and vimentin, and analyzed by flow cytometry after gating on nucleated (propidium iodide-stained) cells and excluding doublets. A majority of cells stained positively for either nestin (65% positive in Fig. 2B ) or vimentin (72% positive), as compared to isotype controls (2.1% positive). A broad distribution of fluorescence intensity was observed, and the cells remaining in the negative region of the dot plot appeared to be weakly stained.
Label incorporation kinetics in progenitor cells
In order to characterize the proliferation kinetics of gradient-enriched hippocampal progenitor cells, Swiss Webster mice were labeled continuously with 10% 2 H 2 O in drinking water, starting at 10 weeks of age; hippocampal progenitor cells were isolated after various labeling times, and 2 H incorporation into DNA, analyzed by GC/MS, was used to determine the fraction of cells that had incorporated the label through cell division (Fig. 2C ). Approximately 16% of cells incorporated label at plateau, with a half-life within this dividing population of about 2.7 weeks; the majority of cells continued to be unlabeled over the course of a year. This is consistent with a "kinetic subpopulation" pattern wherein a preponderance of non-dividing precursors is present with a subset of actively dividing cells that enters and exits the pool (by differentiation or death).
The baseline rate of progenitor proliferation was strain-dependent ( Fig 2D) . proliferation rate was observed in C57Bl/6 mice, whereas the 129SvEv mice had the lowest rate of proliferation.
The fraction of new cells in whole hippocampal tissue of C57Bl/6 mice after 3, 7 or 14 days of labeling was 0.7 ± 0.01%, 1.3 ± 0.3% and 2.9 ± 0.6% respectively. Thus, gradient isolation enriched for proliferating cells, and the consistency of the labeling results indicated that the cell isolation method was highly consistent in this regard.
Effects of anti-depressant drugs on progenitor cell proliferation in rodent hippocampus
Male Swiss-Webster mice (Fig. 3A) or Sprague-Dawley rats (Fig. 3B ) were treated for 3 weeks with anti-depressant drugs of different classes: an SSRI (fluoxetine, 10 mg/kg/day), a tricyclic, (imipramine, 20 mg/kg/day) or an SNRI (venlafaxine, 10 mg/kg/day). After labeling with 2 H 2 O during the last week of treatment, antidepressant-treated animals from all groups showed a significant increase in the progenitor cell proliferation rate in the hippocampus (Fig 3A and 3B ).
Both baseline proliferation and the magnitude of the drug effects were somewhat different between mice and rats, however. Fluoxetine treatment produced a significant (p < 0.01) increase in the hippocampal progenitor cell proliferation in C57Bl/6, 129SvEv, Swiss Webster, and Balb/c mice ( Fig 3C) . The percent stimulation of progenitor cell proliferation by fluoxetine was similar across strains.
Effects of anti-depressant treatment on survival and differentiation of newly divided cells
A "pulse-chase" protocol was used to assess the survival and differentiation of progenitor cells were then discontinued, and the animals were followed for another 4 weeks, after which time intact neurons or neuronal nuclei were isolated for analysis of DNA labeling. weeks after the end of a 3-week labeling period (Fig 4, A 
Effect of retinoid or glucocorticoid administration on progenitor cell proliferation
We also evaluated the activity of a retinoid and a glucocorticoid on hippocampal progenitor cell proliferation. Male 129SvEv mice were treated with isotretinoin (1 or 3 mg/kg, i.p.) for 3 weeks and labeled with 10% 2 H 2 O in the final 10 days of treatment. There was a dose-dependent decrease in hippocampal progenitor cell proliferation following retinoid treatment (Fig 5A) .
Treatment with 3 mg/kg dose of isotretinoin produced a 38% reduction over baseline which was statistically significant (p < 0.05) compared to vehicle-treated controls.
This article has not been copyedited and formatted. The final version may differ from this version. Male Swiss Webster mice were treated with prednisolone (5 or 40 mg/kg in diet) and labeled with 8% 2 H 2 O for 4 weeks. These mice received a slightly different treatment and labeling protocol since they were part of a study investigating the effects of glucocorticoid treatment on several metabolic pathways concurrently. Prednisolone treatment produced a dose-dependent significant (p < 0.01) decrease in hippocampal progenitor cell proliferation ( Fig   5B) . Progenitor cell proliferation was significantly (52%) reduced at the 40 mg/kg dose, compared to untreated controls, and showed a trend toward reduction at the 5 mg/kg dose.
Use of the hippocampal progenitor cell proliferation assay to screen drugs
Next, we explored the feasibility of using hippocampal progenitor cell proliferation as a screen for candidate neurogenic agents. To this end, a panel of approved drugs with known or suspected pleiotropic actions (Table 1) , but not previously known to have neurogenic activity in normal murine hippocampus, was tested for their effects on proliferation of hippocampal progenitor cells in Swiss Webster mice (Fig. 6) . Two of these agents were found to increase the rate of progenitor cell proliferation. The hydroxymethyl-glutaryl CoA (HMGCoA) reductase inhibitor (statin), atorvastatin (10 mg/kg p.o.), and the anticonvulsant, topiramate (100 mg/kg in diet), each given daily for 3 weeks, significantly increased progenitor cell proliferation, measured by 2 H 2 O labeling during the third week. The increases were of a similar magnitude as observed with the positive controls, fluoxetine and imipramine (Fig. 6) . No stimulatory effects were seen for 9 other drugs given by various routes (diet, drinking water, oral gavage, or i.p.) at daily doses reported in the literature to be pharmacologically active for other actions (Table 1 ).
In follow-up studies, we assessed dose-response relationships of the compounds with stimulatory activity and tested other agents in their classes (statins and anticonvulsants).
Topiramate produced a dose-dependent increase in the proliferation of hippocampal progenitor cells of 129SvEv mice (Fig 7A) . Oral treatment with 30 mg/kg/day produced an approximately 70% increase over baseline proliferation, approaching a plateau at higher doses (100 and 150
This article has not been copyedited and formatted. The final version may differ from this version. (Hao et al., 2004) , but the activity of oxcarbazepine is a novel finding. The other anticonvulsants either had no effect on progenitor cell proliferation or were slightly
inhibitory at the single doses tested. We conclude that a subset of anticonvulsants is neurogenic, as judged by DNA labeling of hippocampal progenitors.
The stimulatory action of statins on hippocampal progenitor cell proliferation was also confirmed and extended in dose-response studies, using atorvastatin or simvastatin. Treatment of 129SvEv mice with increasing doses of atorvastatin (1, 3, 10, 30 mg/kg in diet) produced a dose-dependent increase in hippocampal progenitor cell proliferation, with the maximal (68% increase over baseline) effect seen at the 3 mg/kg dose ( Fig 8A) . Chronic oral treatment with another HMGCoA reductase inhibitor, simvastatin, also produced a dose-dependent increase in the proliferation of precursor cells (Fig 8B) in the hippocampus of 129SvEv mice. This more lipophilic statin showed significant stimulatory activity at the 10 and 30 mg/kg doses.
This article has not been copyedited and formatted. The final version may differ from this version. (Kempermann et al., 1997) . Most importantly for drug studies, 2 H 2 O labeling qualitatively and quantitatively reproduced the known enhancing effects of antidepressants of various classes on hippocampal progenitor cell proliferation (Malberg et al., 2000; Santarelli et al., 2003) as well as the known inhibitory effect of isotretinoin on hippocampal progenitor cell proliferation (Crandall et al., 2004) , and the pro-neurogenic activity of valproate (Hao et al. 2004 ). We conclude that, 2 H 2 O labeling generates similar results and reveals the same neurogenic drug actions as BrdU labeling.
For screening purposes, we chose to analyze progenitor cells, rather than mature neurons, even though labeling of both was increased by antidepressants. Progenitor cells comprise the majority of proliferating cells in the hippocampus, and sufficient 2 H label for quantification is incorporated into DNA of gradient-enriched progenitors after only 7-10 days of JPET # 110510 20 antidepressants exhibit a lag period of about 10 days before stimulating neurogenesis in rodent hippocampus (Santarelli et al., 2003) , we designed our screening experiments for 3 weeks of treatment, with 2 H 2 O labeling for the last 7-10 days. The lag between drug treatment and labeling can be shortened for detecting early onset of action of novel agents. Secondly, we were able to exploit the increased throughput of the 2 H 2 O progenitor cell proliferation assay to screen a sizable panel of approved drugs for previously unknown neurogenic effects in the hippocampus. Two of the 11 agents tested initially, atorvastatin and topiramate, increased progenitor cell proliferation, and these findings were robust in follow-up dose-response studies. Moreover, the proliferative activity of these agents appeared to be shared by other drugs of their class: a second statin, simvastatin, showed stimulatory activity, as did another two of 12 structurally diverse anticonvulsants tested, oxcarbazepine and valproate.
This surprisingly high "hit" rate supports our notion, discussed in detail elsewhere , that unanticipated cross-talk of drug actions on apparently off-target pathways in vivo might be more common than previously thought, due to unappreciated connectivity relationships in complex metabolic networks. In the case of neurogenesis, this makes sense in view of the recognized complex regulation of neurogenesis through sensory input, neurotransmitters, hormones, and neurotrophic factors such as brain derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), insulin growth factor (Warner- Schmidt and Duman, 2006) , and several other known and unknown pathways. The drug activities that we uncovered also seem plausible, after the fact, based on published literature. Atorvastatin has been reported to boost neurogenesis in the hippocampus and subventricular zone after middle cerebral artery occlusion , a model for stroke (Chen et al., 2003) , but drug effects in uninjured brain were not measured in that study. Increased expression of VEGF and BDNF may mediate the neurogenic effect of atorvastatin in both stroke-induced (Chen et al., 2005) and in unmanipulated animals. Moreover, statins also alter expression of genes associated with apoptosis, cell growth and signaling (Johnson-Anuna et al., 2005) . The proliferation-stimulating activities of oxcarbazepine and topiramate are plausible, given published results with valproate, although these results would have been difficult to predict, as many anticonvulsants did not increase progenitor cell proliferation. Although the exact mechanism of neurogenic activation by some anticonvulsants remains unknown, these drugs influence several neurotransmitter systems, as well as intracellular signaling cascades, such as the extracellular signal regulated kinase pathway which has been shown to be activated by the neurogenic anticonvulsant valproate (Hao et al. 2004 ). The inhibition of hippocampal progenitor cell proliferation by the synthetic corticosteroid analogue, prednisolone, confirms the suppressive effect of glucocorticoids, since similar effects have been reported for corticosterone and dexamethasone (Cameron and Gould, 1994; Kim et al., 2004) .
Intriguingly, the novel pro-and anti-neurogenic drug effects that we discovered closely parallel the known behavioral effects of these drugs. Retinoid therapy may cause depression in humans as a side-effect of treatment (Hull and D'Arcy, 2003) . Similarly, conditions exhibiting hypercortisolism (Cushing's syndrome, stress, glucocorticoid therapy) are also associated with clinical depression (Mitchell and O'Keane, 1998) . Conversely, anticonvulsants have been used as augmentation therapy in depression (Hantouche et al. 2005) ; differential neurogenic activity may guide the choice of anticonvulsants for this therapeutic use. Moreover, there is increasing evidence that statins may have utility in the treatment of neurological diseases (Menge et al., 2005) . Long-term use of statins has been shown to be associated with reduced risk of anxiety, Young-Xu et al., 2003) . In a trial for Alzheimer's disease, patients treated with atorvastatin for 1 year showed significant improvement of depression (Sparks et al., 2005) . Together with our observations of progenitor cell stimulatory activity of these drugs, these findings provide further support for the neurogenic theory of depression and indicate that in vivo screens for neurogenesis may be useful in the discovery and preclinical validation of novel antidepressants.
Finally, hippocampal neurogenesis is involved in other biological processes besides depression. Since neurogenesis plays a significant role in synaptic plasticity, disorders of learning and memory may be amenable to discovery efforts using this as a biomarker.
Neurogenesis may also be a therapeutic target for other conditions, such as traumatic brain injury, stroke, and Alzheimer's disease.
In conclusion, 2 H 2 O labeling represents a quantitative, reproducible and relatively highthroughput in vivo method for measuring hippocampal progenitor cell proliferation, which is closely linked to neurogenesis and is useful for screening and discovering novel neurogenic stimulatory drugs. Statins and certain anticonvulsant agents were discovered to have potent stimulating activity and may have therapeutic uses based on this activity.
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